Effect of roxadustat on serum metabolome and lipidome in patients with end-stage renal disease and erythropoiesis-stimulating agent resistance

BACKGROUND: Roxadustat is a newly marketed hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia in patients with end-stage renal disease (ESRD). While clinical trials have demonstrated the therapeutic effects of roxadustat in patients with ESRD who are resistant to erythropoies...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lichao, Wu, Yulin, Li, Yongjiang, You, Lianlian, Liu, Xinyu, Wang, Zhihong, Xiao, Jia, Zhang, Shuang, Xu, Tianrun, Wang, Xiaolin, Li, Qi, Hu, Chunxiu, Xu, Guowang, Liu, Shuxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622472/
https://www.ncbi.nlm.nih.gov/pubmed/36330384
http://dx.doi.org/10.21037/atm-22-4451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622472/
https://www.ncbi.nlm.nih.gov/pubmed/36330384
http://dx.doi.org/10.21037/atm-22-4451

Ejemplares similares